Jiangzhong pharmaceutical: it is estimated that the total operating revenue in the first quarter of 2022 will be about 890 million yuan, with a year-on-year increase of about 30%

Survival Rules for Turbulent Times: A Compilation of the 20 Most Unmissable Core Insights from the 2026 Tsinghua PBCSF Forum

A dialogue between Zhu Min, former Deputy Governor of the People's Bank of China and former Vice Managing Director of the International Monetary Fund; Michael Spence, 2001 Nobel Prize winner in Economics and Philip H. Knight Professor Emeritus of Management at Stanford Graduate School of Business; and Masaaki Shirakawa, former Governor of the Bank of Japan, at the 2026 Tsinghua PBCSF Global Finance Forum.

Runjian Signs US$200 Million Overseas AI Inference Contract, Keeping Computing Resources in China

Runjian（润建股份）disclosed on October 18 that its wholly owned subsidiary Wuxiang Yungu（五象云谷）had signed a one-year AI token services contract with an unidentified overseas company. The agreement includes a US$200 million minimum annual purchase commitment, equivalent to approximately CNY 1.338 billion, with computing resources hosted in China and services accessed remotely through an API.

China Proposes Export Restrictions on 23 AI Technologies, Keeps API Services Outside Large-Model Transfer Rules

China’s Ministry of Commerce and Ministry of Science and Technology published proposed additions to the country’s technology-export catalogue on October 16, covering 23 AI technologies. Accompanying guidance distinguishes transfers of restricted technology from services such as overseas API access, while a temporary registration requirement has already taken effect.

Semight Instruments Plans Hong Kong Listing to Broaden Offshore Financing Options

Semight Instruments（联讯仪器）, a Suzhou-based supplier of test instruments and equipment, has secured board approval to pursue an H-share listing on the Hong Kong Stock Exchange’s Main Board. The proposal advances the company’s plans to broaden offshore financing access, although shareholder approval and regulatory procedures remain outstanding.

CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM

There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?